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Women and Ischemic Heart Disease
Evolving Knowledge
Leslee J. Shaw, PHD,† Raffaelle Bugiardini, MD,‡ C. Noel Bairey Merz, MD*
Los Angeles, California; Altanta, Georgia; and Bologna, Italy
Evolving knowledge regarding sex differences in coronary heart disease is emerging. Given the lower burden of
obstructive coronary artery disease (CAD) and preserved systolic function in women, which contrasts with greater
rates of myocardial ischemia and near-term mortality compared with men, we propose the term “ischemic heart
disease” as appropriate for this discussion specific to women rather than CAD or coronary heart disease (CHD).
This paradoxical difference, where women have lower rates of anatomical CAD but more symptoms, ischemia,
and adverse outcomes, appears linked to abnormal coronary reactivity that includes microvascular dysfunction.
Novel risk factors can improve the Framingham risk score, including inflammatory markers and reproductive
hormones, as well as noninvasive imaging and functional capacity measurements. Risk for women with obstruc-
tive CAD is increased compared with men, yet women are less likely to receive guideline-indicated therapies. In
the setting of non–ST-segment elevation acute myocardial infarction, interventional strategies are equally effec-
tive in biomarker-positive women and men, whereas conservative management is indicated for biomarker-
negative women. For women with evidence of ischemia but no obstructive CAD, antianginal and anti-ischemic
therapies can improve symptoms, endothelial function, and quality of life; however, trials evaluating impact on
adverse outcomes are needed. We hypothesize that women experience more adverse outcomes compared with
men because obstructive CAD remains the current focus of therapeutic strategies. Continued research is indi-
cated to devise therapeutic regimens to improve symptom burden and reduce risk in women with ischemic
heart disease. (J Am Coll Cardiol 2009;54:1561–75) © 2009 by the American College of Cardiology
Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.04.098A
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(uring the past several decades, an evolving knowledge re-
arding sex differences in coronary heart disease (CHD) has
merged. Prevalence, symptom manifestation, and pathophys-
ology for CHD vary between women and men. Annual CHD
opulation statistics continue to report a greater number of
eaths for women than men (455,000 vs. 410,000) (1).
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ty for women, reductions lag behind those realized for men
2), including mortality increases among younger women (3).
he most recent Centers for Disease Control and Prevention
ata reveal that 1 in 2.6 women die from CHD contrasted with
in 4.6 from cancer (4). Current projections indicate a
ontinued increase in CHD, given our aging population and
pidemics of obesity, diabetes, and the cardiometabolic syn-
rome (1,2,5,6). Notably, cardiac death remains the leading
iller of women at all ages (1,7,8).
Among clinical cohorts, paradoxical sex differences are
bserved where women have less anatomical obstructive coro-
ary artery disease (CAD) and relatively preserved left ventric-
lar function yet greater rates of myocardial ischemia and
ortality compared with similarly aged males (5,9–11). Ac-
ordingly, the term ischemic heart disease (IHD) is more
ppropriate for a discussion specific to women rather than
AD or CHD. Data from the National Institutes of Health-
ational Heart, Lung and Blood Institute-sponsored WISE
Women’s Ischemia Syndrome Evaluation) and related studies
mplicate abnormal coronary reactivity (12), microvascular
ysfunction (13), and plaque erosion/distal microembolization
14,15) as contributory to a female-specific IHD pathophysi-
logy. Thus, knowledge beyond an anatomical description of
w
s
m
a
d
e
a
f
h
c
d
g
r
(
d
s
n
d
R
M
t
g
d
d
O
h
i
p
m
r
a
b
m
f
t
1
w
c
o
n
m
N
T
(
n
W
(
a
i
i
m
a
i
r
i
(
a
i
o
d
o
w
o
h
c
i
e
1
1562 Shaw et al. JACC Vol. 54, No. 17, 2009
Women and Ischemic Heart Disease October 20, 2009:1561–75obstructive CAD may provide im-
portant clues to IHD risk detec-
tion and treatment for women.
This review outlines our evolv-
ing knowledge of pathophysiol-
ogy and mechanisms of IHD in
women. We include clinical
studies addressing sex-specific is-
sues in IHD prevalence and
prognosis, traditional and novel
risk factors, screening and diag-
nostic testing, as well as thera-
peutic management strategies.
We propose models for applica-
tion of our emerging knowledge
on IHD in women to clinical
practice, as well as forward novel
hypotheses for investigation. Fi-
nally, although it is unknown to
what extent the described issues
are specific or simply more prev-
alent in women, it is likely that
the outlined concepts should also
be applicable for men.
Prevalence of
IHD in Women
In addition to an absolute greater
number of women dying from
IHD, a greater proportion of
women die of sudden cardiac
death before their arrival at a
hospital (52%) contrasted with
42% of men (16,17). Recent data
(18) report significant decreases
in sudden cardiac death in men
with essentially no change in
omen. Symptomatic women more often have persistent
ymptoms requiring more hospitalizations compared with
en, accompanied by lower ratings of general well-being
nd limitations in their abilities to perform activities of
aily living (19,20). Notably, these adverse outcomes are
xperienced by women of all ages despite a lesser extent
nd severity of obstructive CAD and better systolic
unction compared to men (11). Relatively greater CAD
ealth care costs are incurred in women where resource
onsumption patterns are characterized by: 1) more frequent
iagnoses of angina, office visits, and hospitalizations; 2)
reater myocardial infarction (MI) mortality; and 3) greater
ates of heart failure hospitalization as compared with men
22–24). Thus, IHD in women presents a unique and
ifficult challenge for clinicians as the result of a greater
ymptom burden, functional disability, greater health care
eeds, and more adverse outcomes as compared with men
Abbreviations
and Acronyms
ACE  angiotensin-
converting enzyme
ACS  acute coronary
syndrome
CAC  coronary artery
calcium
CAD  coronary artery
disease
CCTA  coronary
computed tomographic
angiography
CHD  coronary heart
disease
cIMT  carotid intima-
media thickness
CMR  cardiac magnetic
resonance
CRP  C-reactive protein
CVD  cardiovascular
disease
FRS  Framingham Risk
Score
hsCRP  high-sensitivity
C-reactive protein
IHD  ischemic heart
disease
MET  metabolic
equivalent
MI  myocardial infarction
PCI  percutaneous
coronary intervention
PET  positron emission
tomography
STEMI  ST-segment
myocardial infarctionespite a lower prevalence and severity of anatomical CAD. iisk Factors for IHD in Women
ore than 80% of midlife women have 1 or more tradi-
ional cardiac risk factors (25). Women have, on average,
reater blood cholesterol levels than men after their 5th
ecade of life (10) and exhibit mild decreases in high-
ensity lipoprotein cholesterol after menopause (1,26).
besity is prevalent in one-third of women, including 7%
aving a body mass index 40 kg/m2 with associated
ncreased mortality (27,28). Hypertriglyceridemia is a more
otent independent risk factor for women as compared with
en (26,29). Diabetic women have significantly greater
ates of IHD mortality compared with diabetic men (30,31)
nd an elevated 3.3-fold IHD risk compared with nondia-
etic women (32). Importantly, 30-year trends reveal
arked cardiovascular disease (CVD) mortality reduction
or diabetic men but not for diabetic women (33).
The rate of IHD mortality increases with the number of
raditional cardiac risk factors, with 30-year death rates (per
0,000 person-years) ranging from 1.5 to 9.1 for women
ith 0 to 2 risk factors (34). Clustering of risk factors is
ommon after menopause, notably the combination of
besity, hypertension, and dyslipidemia (35–39); this phe-
omenon is potentially related to hormonally-mediated
etabolic disturbances.
ovel Risk Factors for IHD in Women
raditional risk factors and the Framingham risk score
FRS) underestimate IHD risk in women (40–45), whereas
ovel risk markers improve risk detection (13,46,48,49).
omen have, on average, greater mean C-reactive protein
CRP) measures compared with men, a sex difference
pparent at the time of puberty (50). This difference in CRP
s consistent with the 2- to 50-fold greater frequency of
nflammatory-mediated autoimmune diseases, such as rheu-
atoid arthritis or systemic lupus erythematosus, in women
s compared with men (51), suggesting a prominent role for
nflammation in IHD sex differences. Indeed, the relative
isk of future IHD events increases proportionally with
ncreasing levels of high-sensitivity C-reactive protein
hsCRP), acting synergistically with other risk factors to
ccelerate IHD risk in women (47,48,52–55). A number of
nflammatory measures, including hsCRP, are related to
ther IHD risk markers such as the cardiometabolic syn-
rome, type 2 diabetes, and heart failure (53,56,57). The use
f multiple biomarkers improves IHD risk assessment in
omen (58–60).
We and others have further demonstrated that disruption
f ovulatory cycling, indicated by estrogen deficiency and
ypothalamic dysfunction (61) or irregular menstrual cy-
ling (62) in premenopausal women is associated with an
ncreased risk of coronary atherosclerosis and adverse CVD
vents. Polycystic ovary syndrome is prevalent in 10% to
3% of women and is linked with a clustering of risk factors,
ncident type 2 diabetes mellitus (63), and adverse IHD
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October 20, 2009:1561–75 Women and Ischemic Heart Diseasevents post-menopausally (64). The cardiometabolic syn-
rome is a clustering of risk factors, including at least 3 of
he following: insulin resistance, dyslipidemia (increased
evels of triglycerides, decreased levels of high-density li-
oprotein cholesterol), hypertension, or abdominal obesity
nd is frequently associated with alterations in endogenous
strogens and androgens in women (36,62,65). Investiga-
ion into the optimal utilization of novel risk factors for
HD risk stratification in women is needed.
isk Assessment in Women by the
se of Traditional Risk Factors and Scores
he FRS is used to classify patients’ 10-year risk of CAD
eath or MI to determine the appropriate level of therapeu-
ic intervention for both low-density lipoprotein cholesterol
nd hypertension (66,67). Patients at the greatest risk
hould receive the most intensive therapeutic and lifestyle
ecommendations (i.e., secondary prevention goals). How-
ver, the FRS classifies 90% of women as low risk, with
ery few assigned a high-risk status before the age of 70
41). The FRS is best used to risk stratify populations and
nderestimates individual patient risk, notably for women
43–45).
The Reynolds risk score is a sex-specific tool recently
evised from large derivation (n  24,588) and validation
n  8,158) cohorts of women (68). This score uses the
ollowing equation: 0.0799  age  3.137  natural
ogarithm (systolic blood pressure)  0.180  natural
ogarithm (hsCRP)  1.382  natural logarithm (total
holesterol) –1.172  natural logarithm (high-density li-
oprotein cholesterol)  0.134  hemoglobin A1c (%) (if
iabetic)  0.818 (if current smoker)  0.438 (if family
istory of premature MI). When compared with the FRS,
se of the Reynold’s score resulted in risk reclassification in
40% of intermediate FRS women (68).
The authors of a few recent reports (43,44) also have
xamined the prevalence of subclinical atherosclerosis
ithin female FRS subsets. In a recent cross-sectional study
f 2,447 consecutive, clinically referred asymptomatic, non-
iabetic women, 84% of those with significant coronary
rtery calcification (CAC) were classified with a low FRS
43). These data underscore the imprecision of FRS esti-
ates in women and the prevalent, undetected burden of
therosclerosis in females.
oninvasive Imaging of Atherosclerosis
here is a growing body of evidence on the use of athero-
clerotic imaging. In women, the prevalence of an ankle
rachial index 0.90 increases with age (ranging 5% for
60 years to 10% to 35% for 60 to 80 years) and is more
revalent in Black and Hispanic women (69,70). The
azard for death with an ankle brachial index 0.90 is 2.7
95% confidence interval [CI]: 2.0 to 3.6) for women and
.3 (95% CI: 2.7 to 4.1) for men (71). Carotid intima-media
hickness (cIMT) is another imaging marker that is a palidated measure of risk for both women and men (72–74).
low-risk cIMT is associated with a 1% 10-year IHD
isk versus 10% for a high-risk cIMT (75), with a
elatively greater risk predicted for women than men (76).
he CAC is another imaging measure that is highly
orrelated with traditional risk factors (77) but uncorrelated
ith hsCRP (78). It lags by nearly a decade in incidence for
omen, similar to obstructive CAD (49,79–84). From the
HLBI Multi-Ethnic Study of Atherosclerosis (44),
omen with a CAC score 300 had an annual IHD event
ate of 2.2%, thus achieving NCEP CHD risk-equivalent
tatus. The IHD event risk for women with a high-risk
AC score and multiple risk factors is 10% greater in
omen than men (49,83), supporting the notion that
omorbidity disproportionately accelerates risk in women.
ymptom Assessment and
revalence of Ischemia in Women
he evaluation of women with symptoms suggestive of
HD is hampered by the definition of “typical” angina,
erived from largely male populations where exertional
omponents are more reflective of male patterns of presen-
ation (85,86). Women report more angina despite lower
ates of obstructive CAD (11,87–89). In a recent meta-
nalysis (90) of 74 reports from 13,311 women and 11,511
en, angina prevalence was 11% to 27% greater for women
65 years of age yet similar in the elderly age 75 years.
omen with typical or atypical chest pain symptoms
nonexertional or prolonged discomfort unrelieved by rest)
ave calculated obstructive CAD probabilities substantially
ess than that of men (91–93) and among those undergoing
oronary angiography, as many as 50% of women do not
ave obstructive CAD (93,94).
More than one-half of symptomatic women without
bstructive CAD continue to have signs and symptoms of
schemia, undergo repeat hospitalization and coronary an-
iography, with continued consumption of CAD health-
are resources that often are the result of diagnostic and
herapeutic uncertainty (20,24). Data from the Women’s
ealth Initiative document that women with nonspecific
hest pain have a 2-fold greater risk for nonfatal MI (95),
hereas WISE data demonstrate increased rates of mortal-
ty in women with chest pain and no obstructive CAD (96),
nderscoring that prognosis in these women is not benign.
“Normal” coronary angiograms, defined as no visible
bstructive CAD (luminal irregularities 50% stenosis) are
lso reported more frequently in women with acute coronary
yndromes (ACS). In a recent large series from 600 U.S.
ospitals in 459,941 patients with ACS, the adjusted odds
or obstructive CAD were 50% lower for women as com-
ared with men (11). For women presenting with ACS/ST-
egment elevation myocardial infarction (STEMI), 10% to
5% of women as compared with 6% to 10% of men have no
bstructive CAD (97–100). Of the estimated 1.4 million
atients discharged after an ACS each year, 600,000 are
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Women and Ischemic Heart Disease October 20, 2009:1561–75omen (1). Among women, the 10% to 25% rate of
normal” angiography (101) translates into 60,000 to
50,000 women with ACS/MI having nonobstructive
AD. Specific investigation is needed to understand the
aradox whereby women have less obstructive CAD and less
evere MIs yet worse clinical outcomes compared to men.
he higher mortality compared with men has been attrib-
ted to advanced age, comorbidity (5,10,102,103), and
nderutilization of guideline care among women (104); yet,
he largest mortality gap is observed in younger women,
ith several studies (105,106) demonstrating persistent sex
ifferences despite covariate adjustment.
xercise Electrocardiography (ECG) in Women
linicians often rely on exercise ECG to assess the risk of
HD. The exercise ECG has a lower sensitivity and speci-
city (1 mm ST-segment depression65%) for detection
f obstructive CAD in women compared with men (107), in
art as the result of lower obstructive CAD prevalence (i.e.,
ayesian theory). In several large female cohorts, significant
xertional ST-segment depression did not differ between
urvivors and nonsurvivors (108,109), although marked
T-segment changes (2 mm horizontal or downsloping)
ccurring at low workloads or persisting into recovery
onfirm high-risk status for women (110). Combining
ariables such as exercise duration and ST-segment changes
nto the Duke Treadmill Score accurately predicts IHD
ortality in women (111,112). From the St. James Women
ake Heart Study of 5,392 asymptomatic women, the risk
f death decreased by 9% for every unit increase in the Duke
readmill Score, whereas each metabolic equivalent (MET)
ncrease in exercise capacity decreased mortality by 17%
p  0.001) (111). Women undergoing exercise testing that
se common treadmill protocols are often incapable of
erforming 5 METs (112), a level equivalent to perform-
ng routine activities of daily living (113), elevating their risk
f IHD death or MI by 3-fold (108–110,114). Reduced
unctional capacity (7 METs) portends worsening out-
ome equally among lean and obese women (115). A female
ex-specific nomogram of exercise capacity (in METs) has
een devised and can be applied to estimate average func-
ional abilities for women of diverse ages (116).
oninvasive Cardiac Imaging in Women
tress-induced changes in regional myocardial perfusion or
all motion are accurate markers of IHD risk in women
110,117–120). Although the sensitivity of echocardio-
raphic wall motion abnormalities is diminished in the
etting of an intermediate stenosis or single-vessel obstruc-
ive CAD, the test’s high negative predictive value renders it
seful for younger women (110). Stress-induced changes in
yocardial perfusion have been extensively evaluated in
omen by the use of SPECT imaging with more recent use
f positron emission tomography (PET) and cardiovascular
agnetic resonance (CMR) techniques (110). CThe evidence is substantial that myocardial perfusion
maging effectively risk stratifies women (110,119,120).
ooled myocardial perfusion data in 7,500 women reveal
low annual IHD event rate of 0.6% in the setting of a
ormal study (119). Survival worsens for women with
ultivessel ischemia (120) or moderate-to-severe perfusion
bnormalities, yielding a 5% annual IHD mortality for
omen (121). Because SPECT flow is comparatively as-
essed across the myocardium, it can appear normal in the
etting of global reductions in perfusion attributable to
evere multivessel CAD but also to endothelial or micro-
ascular dysfunction, left ventricular hypertrophy, or cardio-
yopathy. Additional challenges for SPECT in women
nclude the following: 1) limited spatial resolution where
inor perfusion abnormalities may go undetected in smaller
earts; and 2) breast tissue artifact. With regards to the
atter, contemporary techniques that use Tc-99m agents,
rone imaging, and/or attenuation correction algorithms
iminish the frequency of artifact (110). Thus, it is no
onger appropriate to label perfusion abnormalities in the
etting of nonobstructive CAD as “false positives” in women
f accompanied by objective signs of ischemia, such as chest
ain, electrocardiographic abnormalities, or reduced func-
ional capacity caused by the elevated IHD risk (52,106).
he use of 82Rb PET has several advantages in women,
ncluding quantification of absolute values of regional and
lobal myocardial blood flow to assess microvascular disease
flow reserve) and integrated attenuation correction along
ith improved image quality compared with SPECT. The
se of PET has notable advantages for obese women;
owever, there is limited prognostic data with no sex-
pecific reports (122,123). On the basis of recent estimates,
ffective radiation dose appears slightly greater for PET
hen compared with single-isotope rest-stress SPECT
maging (12.6 to 13.5 for 82Rb PET vs. 11.3 to 11.4 for
est-stress Tc-99m SPECT) (124).
Stress CMR imaging uniquely allows the measurement of
ubendocardial perfusion. In an initial report in 19 symp-
omatic women with abnormal stress tests and normal
oronaries, subendocardial ischemia frequently was observed
125). These findings have been validated in a larger cohort
eporting a strong correlation between subendocardial isch-
mia and abnormal coronary reactivity testing (126), al-
hough population heterogeneity has resulted in varying
esults (127). Investigation into the prognostic implications
f CMR subendocardial ischemia with regard to IHD
vents and its association with future chest pain frequency
nd stability is needed.
Coronary computed tomographic angiography (CCTA)
s a noninvasive anatomic technique with a reported high
iagnostic accuracy for obstructive CAD (128,129). In a
eries of 51 women and 52 men, diagnostic sensitivity and
pecificity was similar by sex at 85% and 99% (130);
lthough a recent larger controlled trial demonstrated a
ower specificity of 90% (131). An important limitation for
CTA, and all tests of ionizing radiation exposure, is that
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October 20, 2009:1561–75 Women and Ischemic Heart Diseasemaging should be used cautiously in younger women due to
heightened lifetime cancer risk. CCTA is associated with
ffective radiation doses that average 11.3 mSv for men and
2.7 mSv for women (124). Test protocols emphasizing
eductions in radiation exposure, including ECG-controlled
ube current modulation, prospective gating, minimization
f scan length, and optimization of tube current and voltage,
hould be emphasized in women. Moreover, especially for
ounger women, caution should be applied to use of testing
hat involves ionizing radiation and, in some cases, use of
tress echocardiography or magnetic resonance imaging
echniques may be favorable, in particular for younger
omen.
Importantly, women with angina and confirmatory ische-
ia have an elevated IHD mortality (106). In a recent
eport from an ambulatory population (n  56,441 women
nd 34,885 men), the coronary standardized mortality ratio
as2-fold greater for women 55 to 74 years and increased
o 12-fold greater for those aged 45 to 54 years (132). In
ummary, abnormalities in functional capacity and nonin-
asive imaging are valuable IHD risk predictors in symp-
omatic women. Further work is needed to integrate the use
f existing and novel strategies to optimize IHD risk
etection in women.
oronary Reactivity in Women
omen suffer disproportionately from a variety of general-
zed vascular disorders, including migraine headaches,
aynaud’s phenomenon, and autoimmune arteritis. These
bservations support the influence of lifelong, varying re-
roductive hormone levels related to ovarian cycling, preg-
ancy, peripartum, and menopause are likely related to
ascular function in health and disease (133). Although
nowledge regarding the role of coronary reactivity was
istorically confined to Prinzemetal’s angina, characterized
y abnormal proximal epicardial coronary artery vasospasm
odulated by smooth muscle dysfunction (134), it is now
lear that intramyocardial microvascular arteries (135) me-
iated by endothelial (136) and autonomic nervous system
drenergic pathways (137) are involved.
icrovascular dysfunction. Recent data support a sex-
pecific role for coronary microvascular dysfunction in IHD
athophysiology. Autopsy data from sudden cardiac death
ictims suggest that women have a greater frequency of
oronary plaque erosion and distal embolization compared
ith men (14,15,138–141). Retinal arterial narrowing, a
easure of microvascular disease, is related to CVD events
n women but not men (13). Additional important sex
ifferences in the arterial remodeling/repair response to
njury/atherosclerosis may prove etiologic for the develop-
ent of microvascular dysfunction in women. Although the
nset of atherosclerosis for women temporally lags behind
hat of men, evidence that the combination of smaller
rterial size and more prominent positive remodeling
49,83,142) may lead to a greater role of microvascular tysfunction in IHD in women compared with men (143).
ecently, Han et al. (144) studied patients with obstructive
AD who underwent simultaneous intravascular ultrasound
nd coronary reactivity assessment and demonstrated that men
ave a greater atheroma burden and more diffuse epicardial
ndothelial dysfunction while women have more disease of the
icrocirculation. These factors may influence the higher
ates of angina, ischemia, and ACS in the absence of
bstructive CAD in women supporting coronary microvas-
ular dysfunction as a prominent disorder in women com-
ared to men (113,143).
ndothelial dysfunction. Endothelial function (measured
entrally in the coronary or distally in the peripheral
irculation) contributes to IHD pathophysiology in women.
rachial artery flow-mediated dilation, a peripheral measure
f endothelial function, is impaired in hyperlipidemic,
ypertensive, smoking, and diabetic and women (145) and
xacerbated after the advent of menopause (146). Abnormal
ow mediated dilation in a large cohort of 2,264 postmeno-
ausal women was associated with a 1.3- to 4.4-fold
ncreased IHD risk (p  0.0001) (147). Whether endothe-
ial dysfunction mechanistically is a precursor to the devel-
pment of hypertension, a marker for subclinical atheroscle-
osis, a measure of obstructive CAD severity, or related to
eft ventricular remodeling and diastolic dysfunction is
nknown (5,148,149).
In the coronary circulation, both endothelial-dependent
picardial (endothelial dysfunction) and endothelial-
ndependent (microvascular dysfunction) dysfunction pre-
ict adverse IHD events in patients undergoing diagnostic
ngiography, single-vessel percutaneous coronary angio-
lasty (PCI), or post ACS/MI (150–153). These results are
mportant because restoration of endothelial function is
ssociated with improved outcome. In a study of 400
ypertensive postmenopausal women, improved endothelial
unction was associated with a 7.3-fold lower rate of IHD
vents when compared with women with no improvement
154).
The role that abnormal coronary reactivity plays in
schemia in women without obstructive CAD has only now
een described, and the relative importance of endothelial
nd microvascular dysfunction has been insufficiently ex-
lored. An integrated working understanding of the cascade
f mechanisms and manifestations of ischemia impacting
HD risk in women is reviewed in Figure 1.
nifying Novel Hypotheses of IHD in Women
e propose that coronary microvascular dysfunction is
ore prevalent in women than men as the result of risk
actor clustering, vascular inflammation and remodeling,
nd hormonal alterations and is etiologic for the observed
aradoxical frequent (atypical) symptoms, evidence of isch-
mia, and adverse outcomes. We propose that symptoms
ccurring as the result of coronary microvascular dysfunc-
ion that result in myocardial ischemia should be called
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Women and Ischemic Heart Disease October 20, 2009:1561–75icrovascular angina. A hypothetical model of microvascu-
ar angina in women is depicted in Figure 2. This model
rovides a rationale for why current approaches for detec-
ion of focal obstructive coronary lesions are less effective in
omen with a greater prevalence of nonobstructive CAD.
bnormal coronary reactivity occurs in the setting of
nderlying atheroma vulnerable to clinical instability and
ore progressive disease states. It is for this reason that
dentifying nonobstructive atheroma may provide greater
isk stratification in women. An overarching working
odel of this proposed female-specific IHD pathophys-
ology is depicted in Figure 3. Although the relationship
etween microvascular dysfunction and epicardial athero-
clerosis is not fully understood, a leading hypothesis is
hat it is a single disease process, where response to
ntimal injury may vary related to sex differences in
ascular remodeling and vascular reactivity.
rognosis in Women With IHD
consistent pattern in the literature is a greater mortality in
omen compared with men with acute MI (155–157). In
he Thrombolysis In Myocardial Infarction-II trial, signif-
cantly greater rates of death and reinfarction were observed
n women compared with men at 6 weeks and 1 year, even
fter adjustment for age and comorbidity (158,159). The
uthors of National Registry of Myocardial Infarction-2
105) analyzed data from 384,878 patients and found that
Figure 1 Cascade of Mechanisms and Manifestations of Ischem
Figure illustration by Rob Flewell.mong younger patients (50 years of age) adjusted mor- bality for women was more than twice that of men. The
esults of the PAMI (Primary Angioplasty in Myocardial
nfarction) trial demonstrated that primary PCI after MI
educed the risk of intracranial bleeding resulting in com-
arable survival by sex, in contrast to patients treated with
issue plasminogen activator where in-hospital mortality
rom acute MI was 3.3-fold greater in women than men
160). Although absolute mortality reduction in MI patients
reated with fibrinolytic therapy is similar by sex, there is a
reater rate of mortality after reperfusion with fibrinolytic
herapy in women of all ages (161).
rognosis in women with obstructive CAD. In women
ndergoing invasive coronary angiography, those with obstruc-
ive CAD have a 1.7- to 2.0-fold greater odds of in-hospital
ortality as compared with nonobstructive CAD (p  0.013)
11). In-hospital mortality is greatest for ACS women ranging
rom 22% to 38% for those with 1- to 3-vessel CAD (p 
.0001). The greater short-term mortality includes more fre-
uent complications of reinfarction and greater procedural
omplications, with older age, more diabetes, and greater
omorbidity considered to contribute (5,103,113,162,163). In
recent postinfarction trial, there was a borderline increased
isk of sudden cardiac arrest and resuscitated cardiac arrest that
ccurred within the first week after MI in women (p  0.08),
uggesting a greater acute post-MI instability in women (164).
rognosis in women with nonobstructive CAD. The
rognosis with “normal” coronary arteries co-occurring with
igns and symptoms of myocardial ischemia has historically
aving an Impact on Ischemic Heart Disease Risk in Womenia Heen interpreted as benign (165–167). More recent prog-
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October 20, 2009:1561–75 Women and Ischemic Heart Diseaseostic data in patients with ACS and nonobstructive CAD
o not appear to be consistent with these historical findings,
nd the authors note a 2% risk of death and myocardial
nfarction at 30 days of follow-up (168). Notably, although
majority of these subjects were women, these datasets
nclude men with nonobstructive CAD and comparative
nalyses by sex are needed.
A recent investigation demonstrated that 30% of women
ith chest pain, “normal” angiograms, and endothelial
ysfunction developed obstructive CAD during a 10-year
ollow-up (169). A pooled analysis of women from recent,
arge randomized trials reveals that women with mild CAD
ave a worsening prognosis as compared with those with
ormal coronaries (170). Recently, Gulati et al. (96) re-
orted 5-year CVD event rates of 16.0% for those with mild
AD (stenosis 1% to 49%), 7.9% for those with no coronary
tenosis, and 2.4% in asymptomatic women (p  0.002)
fter adjustment of cardiac risk factors. Despite these
ompelling findings, treatment for women with open coro-
ary arteries remains often reassurance, sedative-hypnotic
rescriptions, and/or repeated hospitalization and coronary
ngiography in response to refractory symptoms (97).
Given the sizeable gap in IHD prognosis between women
nd men, further research into sex-specific pathophysiology
s needed. A model summarizing the factors known to
ontribute to the prognostic risk of IHD events in women
Figure 2 Model of Microvascular Angina in Women
Figure illustration by Rob Flewell. HTN  hypertension; PCOS  polycystic ovary syith and without obstructive CAD is depicted in Figure 4. wreatment of Women With IHD
nvasive strategies for ACS in women. For women with
CS, existing evidence-based guidelines support a stratified
nvasive versus conservative strategy for high- and low-risk
omen (171). Data from a recent meta-analysis of 8 ACS
rials (3,075 women and 7,075 men) were used to compare
isk reduction when an invasive compared versus a conser-
ative strategy was implemented (172). For both women
nd men, an invasive strategy resulted in an equivalent 19%
o 27% relative risk reduction by the use of a composite end
oint of death, MI, or repeat ACS. There were, however,
mportant differences in risk reduction between biomarker-
ositive and -negative women. The invasive strategy was
ssociated with a 33% lower risk of the composite end point
n biomarker-positive women in contrast to a greater risk in
iomarker-negative women, a difference that was not evi-
ent in men. Similarly, although women and men with
CS derive similar benefit from drug-eluting stents (174),
omen have an overall greater mortality with PCI for
TEMI and non-STEMI (173).
onservative strategies for ACS in women. After fibri-
olysis, the 30-day incidence of death or nonfatal MI was
ignificantly lower in women compared with men in the
noxaparin group compared with unfractionated heparin
161), suggesting that sex differences may beneficially im-
act outcomes in women for specific therapies. For both
e.ndromomen and men undergoing PCI, despite greater bleeding
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Women and Ischemic Heart Disease October 20, 2009:1561–75isk in women, the clinical benefit of glycoprotein IIb/IIIa
latelet receptor blockade with abciximab for adverse events
s similar (175). Overall, among patients with ACS treated
ith glycoprotein IIb/IIIa receptor blockade (not undergo-
ng early coronary angiography), men experienced a benefit
ith an odds ratio (OR) of 0.81 (95% CI: 0.75 to 0.89)
ompared with a suggestion of harm in women (OR: 1.15,
5% CI: 1.01 to 1.30); although high-risk women with
levated troponins did derive a benefit (176). The authors of
previous study (177) document that women’s greater risk
f bleeding is attributable in part to a lack of dose adjust-
ent to body size and renal function compared with men. A
ex difference in bleeding risk was not observed when doses
ere adjusted for age and renal function (175). From a large
nternational registry, women with ACS were generally
reated less aggressively, including less acute heparin,
ngiotensin-converting enzyme inhibitors, and glycoprotein
Ib/IIIa inhibitors, and had lower rates of discharge with
spirin, angiotensin-converting enzyme inhibitors, and
tatins as compared with men (104). Application of
uideline-indicated therapy after ACS is associated with
bolishment of the adverse mortality gap in women (178).
edical therapy for IHD in women. As noted previ-
usly, one factor contributing to relatively greater IHD
isk in women is less intensive use of indicated medical
herapy (aspirin, beta-blocker, statin, angiotensin-
onverting enzyme [ACE], therapeutic lifestyle counsel-
ng) (179 –183); despite specific guidelines noting their
Progressive manif
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Figure 3 Overarching Working Model of Ischemic Heart Diseas
Figure illustration by Rob Flewell. CAD  coronary artery disease; PCOS  polycysenefit (6). The Cooperative Cardiovascular Project (184) showed that women received less medical treatment
fter MI, including 5% that received fewer prescriptions
f aspirin at discharge; although they were 5% more likely
han men to receive ACE inhibitors, perhaps as the result
f hypertension. A more recent registry (104) indicates
hat this observation has not changed, with women
eceiving less (indicated) aspirin at discharge (87.5% vs.
0.4%), beta-blockers (80.5% vs. 82.7%), and statins
55.9% vs. 69.4%) compared with men.
reatment of women with obstructive CAD. Undertreat-
ent of women has been attributed to the lower prevalence
f obstructive CAD. Recent data from the Euro Heart
urvey of Stable Angina reported that women with CAD
ess likely received coronary revascularization (OR: 0.70;
5% CI: 0.52 to 0.94, p  0.019) and were less often on
ipid-lowering therapy at 1-year follow-up (76% vs. 81%,
 0.05), despite adjustment for an array of clinical factors
185). In contrast, the CRUSADE (Can Rapid Risk Strat-
fication of Unstable Angina Patients Suppress Adverse
utcomes With Early Implementation of the ACC/AHA
uidelines) registry (104) revealed similar rates of PCI
mong women and men after accounting for the severity of
ngiographic CAD (adjusted OR: 0.97; 95% CI: 0.91 to
.03). The authors of the GRACE (Gender, Race, and
linical Experience) study investigated women with ob-
tructive CAD and demonstrated less use of aspirin (95% vs.
6%), beta-blockers (87% vs. 89%), and statins (75% vs.
7%) compared with men (186). The recent COURAGE
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October 20, 2009:1561–75 Women and Ischemic Heart Diseaseressive Drug Evaluation) trial demonstrated that women
ith CAD and chronic stable angina derive an equal benefit
rom intensive, long-term medical therapy and with no
dded benefit of PCI (Fig. 5) (187).
Thus, the weight of the evidence indicates suboptimal
reatment of women with proven obstructive CAD (188),
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Figure 4 Factors That Have an Impact on the Risk of IHD Even
Figure illustration by Rob Flewell. CAD  coronary artery disease; IHD  ischemic
Figure 5 Relative Hazard (95% CIs) for Death or MI for Women
Reprinted with permission from Boden et al. (187). CI  confidence interval; MI  myocarespite evidence and guidelines supporting effective risk
eduction when applying acute, revascularization, and/or
hronic medical therapies (6,189–191).
reatment of women with ischemia and nonobstructive
AD. Much of the evidence of treatment in women with
onobstructive CAD has focused on improvement in symp-
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Women and Ischemic Heart Disease October 20, 2009:1561–75oms or vascular function. Many anti-ischemic therapies
ave been evaluated, including data that calcium antagonists
educe coronary flow reserve and fail to improve symptoms
192). Beta-blockers, however, are highly effective for im-
roving chest pain symptoms (193). No controlled studies
re available on the effects of nitrates on health status
utcomes in women. Statins and ACE inhibitors improve
ndothelial dysfunction (194,195) and may be of benefit in
atients with nonobstructive CAD (194–196). Beneficial
ffects of statins on the coronary microcirculation have been
ocumented in clinical studies (197). Combinations of
rugs, specifically statins and ACE inhibitors, may amplify
hese benefits (194). However, combination therapy to more
ully attenuate the renin-angiotensin aldosterone system has
ot been explored; additional work is required to determine
he translational value of this treatment. The proven benefit
f exercise training in this population (198) suggests that
echanisms of adrenergic modulation play a role.
Novel therapies have been evaluated in women without
bstructive CAD. Imipramine improves symptoms in pa-
ients with abnormal cardiac pain perception and normal
oronary angiograms; possibly through a visceral analgesic
ffect. It also has anticholinergic and alpha-antagonist
ffects demonstrated both in the coronary and peripheral
irculation (199). Six-month supplementation of L-arginine
mproved endothelial function and symptoms in patients
ith nonobstructive CAD (200), although a recent post-MI
rial demonstrated adverse effects of L-arginine questioning
ts safety (201). Menopausal hormone therapy may improve
motional well-being in postmenopausal women with an-
ina and “normal” angiograms, yet there is no anginal
ymptom benefit for these patients (202).
No randomized trials comparing therapies for risk reduc-
ion and cost effectiveness in women with angina/ischemia
nd “normal” coronary arteries have been conducted. Future
HD research will need to specifically characterize patients
s to the pathophysiologic mechanism(s) of disease, with
egard to the presence or absence of coronary microvascular
ysfunction, to devise optimal clinical trials aimed at im-
roved IHD risk and health status outcomes.
ummary
iven the relatively lower prevalence of obstructive CAD
et the notably greater prevalence of ischemia, symptom
urden, and mortality relative to men, we propose the use of
he term IHD as more appropriate for symptomatic women
n lieu of the terms CAD or CHD. Traditional risk factors
ontribute to accelerating risk for IHD events in women,
nd novel risk markers, including inflammatory markers and
eproductive sex hormones, provide unique value for iden-
ifying at-risk women. More recent specific global risk
cores for women, such as the Reynold’s risk score, and
arkers of subclinical atherosclerosis improve risk detec-
ion. Routinely available diagnostic testing can be used to
ccurately risk stratify women; however, the identifica-ion of compromised functional capacity and evidence of
schemia as markers of an adverse prognosis are particu-
arly important. Given the frequent paradoxical findings
f angina and ischemia in women without obstructive
AD, new data support the use of the term microvascular
ngina to reflect the occurrence of microvascular dysfunc-
ion in IHD pathophysiology in women; models linking
hese findings with symptoms, ischemia, and adverse
utcomes should be tested.
For ACS, new sex-specific guidelines indicate that con-
ervative management is indicated for biomarker-negative
omen; however, interventional strategies are equally effec-
ive in biomarker-positive women and men. Yet, the weight
f evidence documents suboptimal use of evidence-based
uideline therapies in women with IHD compared with
en. Antianginal and antiatherosclerotic strategies are ef-
ective for symptom and ischemia management in symp-
omatic women with evidence of ischemia and no obstruc-
ive CAD; however, they are used infrequently and need to
e evaluated in large outcome trials. The evolving knowl-
dge regarding sex differences in IHD appears to be at the
recipice of our understanding; future investigation should
dentify tailored diagnostic and therapeutic strategies to
ptimize outcomes for women and men (203).
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